Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tough_cookie完成签到 ,获得积分10
刚刚
asdwind完成签到,获得积分10
2秒前
freebird完成签到,获得积分10
4秒前
安风完成签到 ,获得积分10
10秒前
Vigour完成签到 ,获得积分10
11秒前
笨笨千亦完成签到 ,获得积分10
12秒前
千夜冰柠萌完成签到,获得积分10
13秒前
852应助海豚采纳,获得10
17秒前
炎炎夏无声完成签到 ,获得积分10
18秒前
chemistry高完成签到 ,获得积分10
19秒前
21秒前
一行白鹭上青天完成签到 ,获得积分10
21秒前
自转无风完成签到,获得积分10
22秒前
魔术师完成签到 ,获得积分10
22秒前
Flowing完成签到,获得积分10
25秒前
28秒前
风中星月完成签到 ,获得积分10
29秒前
想发一篇贾克斯完成签到,获得积分10
33秒前
聂先生完成签到,获得积分10
39秒前
Yuki完成签到 ,获得积分10
40秒前
XU博士完成签到,获得积分10
48秒前
今后应助沉默安波采纳,获得10
56秒前
aaaa完成签到,获得积分10
1分钟前
无奈山雁完成签到 ,获得积分10
1分钟前
三脸茫然完成签到 ,获得积分0
1分钟前
时尚若雁完成签到,获得积分10
1分钟前
Xu完成签到,获得积分10
1分钟前
幸福耷完成签到 ,获得积分10
1分钟前
tigger完成签到,获得积分10
1分钟前
博比完成签到,获得积分10
1分钟前
feng完成签到,获得积分10
1分钟前
1分钟前
Nexus应助Joy采纳,获得10
1分钟前
Hh完成签到,获得积分10
1分钟前
沉默安波发布了新的文献求助10
1分钟前
aikeyan完成签到,获得积分10
1分钟前
Augenstern完成签到,获得积分10
1分钟前
2275523154完成签到,获得积分10
1分钟前
Joy完成签到,获得积分10
1分钟前
科研摆渡人完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6523260
求助须知:如何正确求助?哪些是违规求助? 8316260
关于积分的说明 17793806
捐赠科研通 5625232
什么是DOI,文献DOI怎么找? 2928180
邀请新用户注册赠送积分活动 1904876
关于科研通互助平台的介绍 1765054